Depression and cardiovascular disease (CVD) are serious concerns for public health. Approximately 280 million people worldwide have depression, while 620 million people have CVD. It has been known since the 1990s that the two diseases are somehow related.
UCB’s anti-tau Alzheimer’s program fails Phase 2 primary endpoint, but highlights positive secondaries
UCB reported Thursday that a Phase 2 study for its anti-tau Alzheimer’s program bepranemab did not meet its primary endpoint. Neither the low dose nor
November 1, 2024